Analysis of Mitogen-Activated Protein Kinases in Bone and Cartilage of Patients with Rheumatoid Arthritis Treated with Abatacept.
Analysis of Mitogen-Activated Protein Kinases in Bone and Cartilage of Patients with Rheumatoid Arthritis Treated with Abatacept.
复制标题
DOI：
10.4137/cmamd.s34424
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Yabuki A
中科院分区：
文献类型：
--
作者：
Kanbe K;Oh K;Chiba J;Inoue Y;Taguchi M;Yabuki A
本研究的目的是分析阿巴肽治疗类风湿关节炎（RA）后骨和软骨中与丝裂原活化蛋白（MAP）激酶相关的组织学变化。共对20例骨和软骨患者进行评估：10例阿巴肽联合甲氨蝶呤（MTX）治疗的RA患者与10例MTX治疗的RA患者（对照组）进行比较。采用苏木精和伊红染色观察骨和软骨的组织学变化，免疫组化检测肿瘤坏死因子-α、白细胞介素-6、CD4 （T细胞）、CD68（巨噬细胞）、核κ b配体受体激活剂、骨保护素、骨桥蛋白、CD29 （β-1整合素）、磷酸化-p38 MAPK （Tyr180/Tyr182）、磷酸化-p44/42 MAPK（细胞外信号调节激酶，ERK1/ERK2）、磷酸化-c- jun n-末端激酶的表达。阿巴肽组骨和软骨MAP激酶中机械受体CD29和机械转导信号蛋白ERK的表达与对照组有显著差异。这些发现表明，MAP激酶中CD29和ERK的增加可能会改变阿巴接受治疗的RA患者骨和软骨的代谢。
The aim of this study was to analyze the histological changes related to mitogen-activated protein (MAP) kinases in bone and cartilage treated with abatacept for rheumatoid arthritis (RA). A total of 20 patients of bone and cartilage were assessed: 10 abatacept with methotrexate (MTX)-treated RA patients were compared with 10 MTX-treated RA patients (control). The histology of bone and cartilage was observed by staining with hematoxylin and eosin and analyzed immunohistochemically for the expression of tumor necrosis factor-α, interleukin-6, CD4 (T cell), CD68 (macrophage), receptor activator of nuclear kappa-B ligand, osteoprotegerin, osteopontin, CD29 (β-1 integrin), phospho-p38 MAPK (Tyr180/Tyr182), phospho-p44/42 MAPK (extracellular signal-regulated kinase, ERK1/ERK2), and phosphor-c-Jun N-terminal kinase. The expressions of CD29 known as mechanoreceptor and ERK known as mechanotransduction signal protein in MAP kinases in the bone and cartilage of patients treated with abatacept were significantly different from those of control. These findings suggest that increases in CD29 and ERK in MAP kinases may change the metabolism of bone and cartilage in RA patients treated with abatacept.